C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) – Pipeline Review, H2 2018

Global Markets Direct’s, ‘C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) – Pipeline Review, H2 2018’, provides in depth analysis on C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Infectious Disease, Oncology, Gastrointestinal and Immunology under development targeting C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)

– The report reviews C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics and enlists all their major and minor projects

– The report assesses C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Allergan Plc

American Gene Technologies International Inc

Auritec Pharmaceuticals Inc

Bristol-Myers Squibb Co

Cytodyn Inc

GlaxoSmithKline Plc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Overview

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Companies Involved in Therapeutics Development

Allergan Plc

American Gene Technologies International Inc

Auritec Pharmaceuticals Inc

Bristol-Myers Squibb Co

Cytodyn Inc

GlaxoSmithKline Plc

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Drug Profiles

(emtricitabine + tenofovir disoproxil fumarate) + maraviroc SR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AG-1105 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-813160 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cenicriviroc Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-004 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-005 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-214096 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRO-140 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SDS-CCR5 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Dormant Products

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Discontinued Products

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Product Development Milestones

Featured News & Press Releases

Jul 30, 2018: Cytodyn announces significantly improved response rate at higher dose of PRO 140 in HIV phase 3 monotherapy trial

Jul 16, 2018: CytoDyn Announces Positive Results from Completed Pivotal PRO 140 HIV Combination Trial

Jul 12, 2018: CytoDyn Announces Leadership Changes to Align with Expanded Focus of PRO 140 to Cancer and Immunological Disorders

Jul 12, 2018: CytoDyn to Expand Strategic Focus with PRO 140 to Cancer and Immunologic Disorders

Jun 26, 2018: New Research Supports Potential for CytoDyn’s PRO 140 to Inhibit Breast Cancer Metastasis

Jun 22, 2018: CytoDyn Announces Productive Pre-BLA Meeting with FDA for PRO 140 Combination Therapy

Jun 20, 2018: CytoDyn Provides Update on Phase 2 Clinical Trial with PRO 140 in GvHD

Jun 11, 2018: CytoDyn ASM Poster Presentation June 9, 2018, at ASM Microbe 2018, Atlanta, GA

Jun 09, 2018: Weekly Injections of CytoDyns PRO 140 in Combination with Optimized Antiretroviral Treatment Shows Long-Acting HIV-1 Viral Suppression

Jun 04, 2018: Results from CytoDyn’s Pivotal PRO 140 Combination Therapy Trial in HIV to be Presented at ASM Microbe 2018 on June 9

May 24, 2018: Results of CytoDyns PRO 140 CD01 Trial and Extension Study Published in HIV Clinical Trials

Apr 11, 2018: CytoDyn to Present Primary Efficacy Endpoint Results from its PRO 140 Pivotal Trial in Late-Breaking Session at ASM Microbe 2018

Mar 29, 2018: CytoDyn Forms Scientific Advisory Board to Advance PRO 140 Development in Immunological Disorders

Mar 14, 2018: CytoDyn to Amend Protocol for PRO 140 Phase 2 Trial in GvHD

Feb 20, 2018: CytoDyn Reports Primary Endpoint Achieved in PRO 140 Pivotal Combination Therapy Trial in HIV Infection

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Allergan Plc, H2 2018

Pipeline by American Gene Technologies International Inc, H2 2018

Pipeline by Auritec Pharmaceuticals Inc, H2 2018

Pipeline by Bristol-Myers Squibb Co, H2 2018

Pipeline by Cytodyn Inc, H2 2018

Pipeline by GlaxoSmithKline Plc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports